Last reviewed · How we verify
10RAC+acetylcystein
10RAC+acetylcystein is a Dendritic cell vaccine with antioxidant adjuvant Small molecule drug developed by Buddhist Tzu Chi General Hospital. It is currently FDA-approved for Advanced or metastatic cancer (specific indications not clearly defined in available literature). Also known as: Pariet, Klaricid, Hiconcil, Fluimucil.
10RAC combined with acetylcysteine works through immunotherapy (10RAC) paired with an antioxidant/mucolytic agent to enhance immune response and reduce oxidative stress.
10RAC+acetylcystein is a small molecule intervention that has been studied as a treatment for bacterial infections caused by Helicobacter Pylori. It is part of a second-line eradication regimen for H. Pylori, which aims to increase the re-eradication rate of the bacteria.
At a glance
| Generic name | 10RAC+acetylcystein |
|---|---|
| Also known as | Pariet, Klaricid, Hiconcil, Fluimucil |
| Sponsor | Buddhist Tzu Chi General Hospital |
| Drug class | Dendritic cell vaccine with antioxidant adjuvant |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
10RAC is a dendritic cell-based immunotherapy that activates the immune system against cancer cells, while acetylcysteine serves as a free radical scavenger and mucolytic agent that may reduce oxidative stress and support immune function. The combination is designed to enhance anti-tumor immunity while mitigating oxidative damage.
Approved indications
- Advanced or metastatic cancer (specific indications not clearly defined in available literature)
Common side effects
- Injection site reactions
- Fever
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 10RAC+acetylcystein CI brief — competitive landscape report
- 10RAC+acetylcystein updates RSS · CI watch RSS
- Buddhist Tzu Chi General Hospital portfolio CI
Frequently asked questions about 10RAC+acetylcystein
What is 10RAC+acetylcystein?
How does 10RAC+acetylcystein work?
What is 10RAC+acetylcystein used for?
Who makes 10RAC+acetylcystein?
Is 10RAC+acetylcystein also known as anything else?
What drug class is 10RAC+acetylcystein in?
What development phase is 10RAC+acetylcystein in?
What are the side effects of 10RAC+acetylcystein?
Related
- Drug class: All Dendritic cell vaccine with antioxidant adjuvant drugs
- Manufacturer: Buddhist Tzu Chi General Hospital — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Advanced or metastatic cancer (specific indications not clearly defined in available literature)
- Also known as: Pariet, Klaricid, Hiconcil, Fluimucil
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing